OPEN IN READ APP
JOURNAL ARTICLE

Immediate Administration of Antiviral Therapy after Transplantation of Hepatitis C-infected Livers into Uninfected Recipients: Implications for Therapeutic Planning

Emily Bethea, Ashwini Arvind, Jenna Gustafson, Karin Andersson, Daniel Pratt, Irun Bhan, Michael Thiim, Kathleen Corey, Patricia Bloom, Jim Markmann, Heidi Yeh, Nahel Elias, Shoko Kimura, Leigh Anne Dageforde, Alex Cuenca, Tatsuo Kawai, Kassem Safa, Winfred Williams, Hannah Gilligan, Meghan Sise, Jay Fishman, Camille Kotton, Arthur Kim, Christin Marks, Sarah Shao, Mariesa Cote, Linda Irwin, Paul Myoung, Raymond T Chung
American Journal of Transplantation 2019 December 30
31887236
The practice of transplanting hepatitis C (HCV)-infected livers into HCV-uninfected recipients has not previously been recommended in transplant guidelines, in part because of concerns over uncontrolled HCV infection of the allograft. Direct-acting antivirals (DAAs) provide an opportunity to treat donor derived HCV-infection, and should be administered early in the post-transplant period. However, evidence on the safety and efficacy of an immediate DAA treatment approach, including how to manage logistical barriers surrounding timely DAA procurement, are required prior to broader use of HCV-positive donor organs. We report the results of a trial in which fourteen HCV-negative patients underwent successful liver transplantation from HCV-positive donors. Nine patients received viremic (nucleic acid testing (NAT)-positive) livers, and started a 12-week course of oral glecaprevir-pibrentasvir (GP) within 5 days of transplant. Five patients received livers from HCV antibody-positive non-viremic donors and were followed using a reactive approach. Survival in NAT-positive recipients is 100% at a median follow-up of 46 weeks. An immediate treatment approach for HCV NAT-positive liver transplantation into uninfected recipients is safe and efficacious. Securing payer approval for DAAs early in the post-transplant course could enable need-based allocation of HCV-positive donor organs irrespective of candidate HCV status, while averting chronic HCV allograft infection.

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read
31887236
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"